Earnings ·
Novo Nordisk raised its full-year adjusted sales and operating profit outlook for 2026 to a growth range of 0% to -6%…
NVONovo Nordisk A S
Novo Nordisk raised its full-year adjusted sales and operating profit outlook for 2026 to a growth range of 0% to -6% at constant exchange rates, up from the previous expectation of -4% to -12%. The revision reflects increased expectations for GLP-1 product sales. For the second quarter of 2026, adjusted sales reached DKK 78,488 million, a 7% increase at CER, while adjusted operating profit rose 11% to DKK 33,389 million. These results exclude non-recurring impacts from 340B Drug Pricing Program provision reversals and DKK 6.3 billion in impairment charges related to intangible pipeline assets, including monlunabant. Novo Nordisk is a global healthcare company specializing in the research, development, manufacturing, and marketing of pharmaceutical products, primarily for diabetes and obesity treatment.